SAB Biotherapeutics, Inc. SABS

3.29 (0.06) (1.79%) as of 25 Sep
Market cap
$304.8M
P/E
0.0×

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Net Income

+8 more TTM periods

18.74 13.27 (0.40) (12.78)
Depreciation & Amortization
3.03 2.99 3.00 3.03
Non Cash Items (Other)
(61.05) (57.36) (47.04) (39.68)
Accounts Payable Change
1.75 1.48 0.91 1.45
Change in other assets and liabilities
0.00 (5.17) (7.72) (5.96)
Operating Cash Flow
(37.53) (44.78) (51.25) (53.94)
Capital expenditures
(0.05) (0.93) (1.91) (3.50)
Long-Term Investments Change (Net)
(110.61) (120.77) (190.11) (198.61)
Investing cash flow
(110.67) (121.71) (192.02) (202.11)
Repayment/Issuance of Debt (Net)
(0.14) (0.42) (0.42) (0.15)
Equity Repurchase (Common, Net)
— — 3.09 92.37
Other financial activities
168.70 168.72 255.73 168.71
Financing cash flow
168.56 168.30 258.39 260.93
Exchange Rate Adjustment
(0.10) (0.21) (0.24) (0.31)
Change in Cash
20.25 1.60 14.88 4.58
Beginning Cash
8.90 8.90 10.50 10.50
Ending Cash
29.15 10.50 25.38 15.08
Stock Based Compensation
2.72 5.21 10.06 16.68
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
1.75 (3.69) (6.81) (4.51)
Investments Change (Net)
(110.61) (120.77) (190.11) (198.61)
Issuance/Purchase of Shares
— — 3.09 92.37

Fold the line items

In millions of $ except per-share values · columns are period end dates